Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;77(2):303-314.
doi: 10.1007/s43440-024-00689-z. Epub 2024 Dec 23.

Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders

Affiliations
Review

Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders

Aleksandra Wisłowska-Stanek et al. Pharmacol Rep. 2025 Apr.

Abstract

Sudden cessation of the drug can cause withdrawal syndrome, discontinuation syndrome, or rebound effect. The common feature of these phenomena is a quick onset, usually limited duration depending on the drug's half-life and remission after restarting the therapy. They are characterized by varying clusters of somatic, autonomic, and psychiatric symptoms. Originally withdrawal syndrome was described for drugs with addictive properties such as barbiturates or benzodiazepines. On the other hand sudden abrupt of antidepressants or antipsychotics may cause discontinuation symptoms including movement or sensory disturbances, sleep disturbances, and hyperarousal but generally of less severity comparing to withdrawal syndrome. The aforementioned syndromes are physiologically based on the predominance of cellular counter-regulations as an effect of the sudden abrupt of a regularly taken medication. Classically the pathogenesis of withdrawal syndrome, based on physical dependence, results in life-threatening, long-lasting manifestations such as, seizures and delirium, different from the treated disease. In turn, these symptoms are not typical for discontinuation syndrome which is not considered as serious and usually spontaneously resolving. In turn, the rebound effect is clinically characterized by the relapse of the disease symptoms that are controlled by medication, but of greater severity than those before treatment.In the current review, we describe withdrawal and discontinuation syndromes associated with selected drugs used in psychiatry and neurology, risk factors, and recommendations for diminishing syndrome occurrence. Knowledge of their pathogenesis and symptoms resulting from drug discontinuation may be helpful in syndrome management and expectantly reduces the risk of diagnostic and therapeutic errors.

Keywords: discontinuation syndrome; neurological drugs; psychiatric drugs; rebound symptoms; withdrawal syndrome.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

Cited by

References

    1. Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA, Vennat B, Llorca PM, Eschalier A. Benzodiazepine dependence: focus on withdrawal syndrome. Ann Pharm Fr. 2009;67(6):408–13. https://doi.org/10.1016/j.pharma.2009.07.001 . Epub 2009 Sep 18. PMID: 19900604. - DOI - PubMed
    1. Klein RL, Harris RA. Regulation of GABAA receptor structure and function by chronic drug treatments in vivo and with stably transfected cells. Jpn J Pharmacol. 1996;70(1):1–15. https://doi.org/10.1254/jjp.70.1 . PMID: 8822084.
    1. Simpson EH, Kellendonk C. Insights About Striatal Circuit Function and Schizophrenia From a Mouse Model of Dopamine D2 Receptor Upregulation. Biol Psychiatry. 2017;81(1):21–30. https://doi.org/10.1016/j.biopsych.2016.07.004 . Epub 2016 Jul 14. PMID: 27720388; PMCID: PMC5121031. - DOI - PubMed
    1. Tsuda M, Shimizu N, Suzuki T. Contribution of glutamate receptors to benzodiazepine withdrawal signs. Jpn J Pharmacol. 1999;81(1):1–6. https://doi.org/10.1254/jjp.81.1 . PMID: 10580363.
    1. Spies LL, Verhoog NJD, Louw A. Acquired Glucocorticoid Resistance Due to Homologous Glucocorticoid Receptor Downregulation: A Modern Look at an Age-Old Problem. Cells. 2021;10(10):2529. https://doi.org/10.3390/cells10102529 . PMID: 34685511; PMCID: PMC8533966. - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources